Asian Society of Gynecologic Oncology International Workshop 2018

Tae‐Wook Kong, Hee‐Sug Ryu, Seung Cheol Kim, Takayuki Enomoto, Jin Li, Kenneth H. Kim, Seung‐Hyuk Shim, Peng‐Hui Wang, Suwanit Therasakvichya, Yusuke Kobayashi, Maria Lee, Tingyan Shi, Shin‐Wha Lee, Mikio Mikami, Satoru Nagase, Myong Cheol Lim, Jianliu Wang, Sarikapan Wilailak, Sang Wun Kim, Sook Hee Hong, David S.p. Tan, Masaki Mandai, Suk‐Joon Chang, Ruby Yun‐Ju Huang, Kimio Ushijima, Jung‐Yun Lee, Xiaojun Chen, Kazunori Ochiai, Taek Sang Lee, Bingyi Yang, Farhana Kalam, Qiaoying Lv, Mohd Faizal Ahmad, Muhammad Rizki Yaznil, Kanika Batra Modi, Manatsawee Manopunya, Dae Hoon Jeong, Arb-aroon Lertkhachonsuk, Hyun Hoon Chung, Hidemichi Watari, Seob JeonJournal of Gynecologic Oncology 2019 · DOI

Abstract

The Asian Society of Gynecologic Oncology International Workshop 2018 on gynecologic oncology was held in the Ajou University Hospital, Suwon, Korea on the 24th to 25th August 2018. The workshop was an opportunity for Asian doctors to discuss the latest findings of gynecologic cancer, including cervical, ovarian, and endometrial cancers, as well as the future of fertility-sparing treatments, minimally invasive/radical/debulking surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy. Clinical guidelines and position statement of Asian countries were presented by experts. Asian clinical trials for gynecologic cancers were reviewed and experts emphasized the point that original Asian study is beneficial for Asian patients. In Junior session, young gynecologic oncologists presented their latest research on gynecologic cancers.

Introduction: Addressing the "One Size Does Not Fit All" Challenge

Clinical guidelines for gynecologic oncology, such as those from the National Comprehensive Cancer Network (NCCN), are largely based on data from Western populations. However, differences in genetics, environment, and healthcare infrastructure mean that Asian patients may require distinct surgical approaches or therapeutic dosages. The 2018 Asian Society of Gynecologic Oncology (ASGO) International Workshop aimed to bridge this gap by synthesizing regional data and standardizing high-tech interventions within the Asian context.

A primary focus was the "MIS Crisis" in cervical cancer, where recent trials suggested that minimally invasive surgery (MIS) might result in worse survival rates than traditional open surgery. The workshop provided a platform to discuss whether these findings apply universally or if specific technical modifications could preserve the benefits of MIS for Asian patients.

Speakers at the ASGO 5th International Workshop presenting on gynecologic oncology.

Methodology and Regional Data Synthesis

The workshop functioned as a multi-disciplinary synthesis of expert presentations, clinical trial updates, and consensus-building sessions. Key areas of focus included:

  • Clinical Review: Analysis of major trials (e.g., LACC, GOG 213, ICON7) and their implications for Asian practice.
  • Surgical Innovation: Evaluation of 3D vs. 2D laparoscopy and radical trachelectomy for fertility preservation.
  • Molecular Oncology: Discussion on PARP inhibitors, BRCA mutations, and Microsatellite Instability (MSI) in tailoring immunotherapy.
  • Policy & Guidelines: Comparison of national guidelines from Japan, Korea, China, and Thailand to identify regional deviations from Western standards.

The discussions drew upon regional registries, such as the Niigata study (Japan) on HPV vaccine effectiveness and the Siriraj Hospital registry (Thailand) on venous thromboembolism, alongside re-analyses of global clinical trials through the lens of Asian patient cohorts.

Key Insights and Innovations

The Asian Advantage and Toxicity Profiles

Asian patients often exhibit better performance status and earlier-stage disease at trial enrollment compared to Western counterparts. However, they also show different toxicity profiles for certain chemotherapies, necessitating localized dosing studies to optimize treatment efficacy and safety.

The MIS Controversy and 3D Laparoscopy

The workshop highlighted that while the LACC trial showed higher recurrence rates in cervical cancer for MIS, the mechanical causes—such as CO2 pneumoperitoneum and tumor spillage during vaginal colpotomy—might be the true culprits. Furthermore, 3D laparoscopy emerged as a "skill equalizer," significantly reducing the learning curve for novice surgeons by restoring depth perception and improving performance scores by nearly 10% in complex tasks.

Drug Repositioning and Molecular Screening

A notable insight was the potential of statins to induce programmed cell death in ovarian cancer by interfering with the "Warburg effect." Additionally, in endometrial cancer, the high concordance (94.1%) between MSI testing and Immunohistochemical (IHC) staining validates IHC as a reliable, cost-effective screening tool for immunotherapy eligibility.

Closing ceremony and group photo of the participants at the ASGO 5th International Workshop.

Significant Outcomes

  • HPV Vaccination: In Japan, the bivalent vaccine is estimated to prevent approximately 82% of invasive cervical cancers.
  • Ovarian Cancer Survival: The addition of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) to interval debulking surgery improved median recurrence-free survival by 3.5 months in specific stage III cohorts.
  • Surgical Precision: 3D systems led to faster operating times and fewer errors in complex suturing compared to 2D systems.

Challenges and Future Directions

Despite these advancements, several hurdles remain. Disparities in healthcare spending and access to high-tech imaging (like PET/MRI) persist across Asian nations. Legal and cultural barriers continue to slow the development of multi-center, international investigator-driven trials within the region. Future work must focus on resolving surgical questions regarding MIS in cervical cancer and increasing clinical trials for rare uterine tumors and mucinous ovarian subtypes.

Summary updated

Abstract

The Asian Society of Gynecologic Oncology International Workshop 2018 on gynecologic oncology was held in the Ajou University Hospital, Suwon, Korea on the 24th to 25th August 2018. The workshop was an opportunity for Asian doctors to discuss the latest findings of gynecologic cancer, including cervical, ovarian, and endometrial cancers, as well as the future of fertility-sparing treatments, minimally invasive/radical/debulking surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy. Clinical guidelines and position statement of Asian countries were presented by experts. Asian clinical trials for gynecologic cancers were reviewed and experts emphasized the point that original Asian study is beneficial for Asian patients. In Junior session, young gynecologic oncologists presented their latest research on gynecologic cancers.
BibTeX
@article{kong2019asian,
  author = {Tae‐Wook Kong and Hee‐Sug Ryu and Seung Cheol Kim and Takayuki Enomoto and Jin Li and Kenneth H. Kim and Seung‐Hyuk Shim and Peng‐Hui Wang and Suwanit Therasakvichya and Yusuke Kobayashi and Maria Lee and Tingyan Shi and Shin‐Wha Lee and Mikio Mikami and Satoru Nagase and Myong Cheol Lim and Jianliu Wang and Sarikapan Wilailak and Sang Wun Kim and Sook Hee Hong and David S.P. Tan and Masaki Mandai and Suk‐Joon Chang and Ruby Yun‐Ju Huang and Kimio Ushijima and Jung‐Yun Lee and Xiaojun Chen and Kazunori Ochiai and Taek Sang Lee and Bingyi Yang and Farhana Kalam and Qiaoying Lv and Mohd Faizal Ahmad and Muhammad Rizki Yaznil and Kanika Batra Modi and Manatsawee Manopunya and Dae Hoon Jeong and Arb-aroon Lertkhachonsuk and Hyun Hoon Chung and Hidemichi Watari and Seob Jeon},
  title = {{Asian Society of Gynecologic Oncology International Workshop 2018}},
  journal = {Journal of Gynecologic Oncology},
  year = {2019},
  doi = {10.3802/jgo.2019.30.e39},
}
Figure